Haemonetics Earnings Call Transcripts
Fiscal Year 2026
-
The conference highlighted record plasma business growth, successful innovation cycles, and robust financial performance, with strong share gains and new product launches like Persona PLUS and PerQseal Elite. The company is focused on sustainable growth, operational improvements, and disciplined capital deployment.
-
Strong Q3 results led to raised full-year guidance for revenue, earnings, and cash flow. Plasma and blood management technologies drove growth, while interventional technologies faced headwinds but are expected to recover in FY27. Margin expansion and robust cash flow support ongoing investments.
-
The conference highlighted strong financial performance, with high-margin growth driven by three core platforms: plasma, TEG, and vascular closure. Recent acquisitions and innovation pipelines are set to expand market leadership, while disciplined capital allocation supports future growth.
-
Second quarter results showed strong organic growth in core products, record margin expansion, and robust cash flow, leading to raised full-year guidance for revenue, EPS, and free cash flow. Plasma and blood management technologies outperformed, while targeted actions are underway to restore growth in interventional technologies.
-
Q1 saw 13% organic revenue growth ex-CSL, 8% adjusted EPS growth, and margin expansion, despite a 4% reported revenue decline from portfolio transitions. Guidance for the year is reaffirmed, with strong performance in Plasma and Hospital segments, and ongoing executional improvements in Interventional Technologies.
Fiscal Year 2025
-
A diversified medtech portfolio now drives double-digit earnings and robust cash flow, with plasma reduced to 38% of revenue and hospital platforms nearing 50%. The company targets high single-digit revenue and double-digit EPS growth, with continued margin expansion and a new three-year LRP to be detailed at an upcoming Investor Day.
-
Delivered strong Q4 and fiscal 2025 results with margin expansion, double-digit growth in hospital and interventional technologies, and robust free cash flow. Fiscal 2026 guidance projects continued margin improvement, double-digit organic growth in key segments, and a new $500 million share repurchase program.
-
The business has shifted to focus on high-growth, high-margin core products, with plasma and interventional technologies driving performance. Plasma growth is supported by technology upgrades and share gains, while hospital and blood management segments show strong momentum. Margin expansion and cash flow improvement are expected, with a conservative outlook for FY26.
-
Q3 saw 4% reported revenue growth and 14% higher adjusted EPS, with record margins driven by portfolio transformation and technology upgrades. Guidance was updated for revenue, margins, and free cash flow, while new long-term plasma contracts and a major Japanese Red Cross win support future growth.
-
Record financial performance and margin expansion are being driven by a strategic shift to high-growth, high-margin products, with plasma and hospital businesses as key engines. Ongoing innovation, M&A, and operational excellence support robust growth and future value creation.
-
Second quarter revenue grew 9% reported and 4% organically, with strong hospital and technology-driven growth offsetting plasma and blood center declines. Adjusted EPS rose 13% year-over-year, and guidance was raised for hospital and organic revenue growth, while margin expansion and capital deployment remain key priorities.
-
Revenue grew 8% reported and 3% organically, with strong hospital and interventional growth offsetting plasma and blood center declines. Guidance for FY 2025 is reaffirmed, with new products and acquisitions driving margin expansion and a robust liquidity position supporting future growth.